CONMED Beats Q1 Estimates, Raises Full-Year Revenue Guidance

summarizeSummary

CONMED Corporation reported first-quarter results that exceeded expectations for both revenue and adjusted EPS, leading the company to raise its full-year organic revenue growth outlook.

check_boxKey Events

• Exceeded Q1 Expectations

  CONMED reported Q1 2026 sales of $317.0 million and adjusted diluted EPS of $0.89, both surpassing analyst expectations and continuing momentum from 2025.

• Raised Full-Year Revenue Guidance

  The company increased its full-year 2026 organic constant currency revenue growth guidance from 4.5%-6.0% to 5.0%-6.5%, reflecting improved performance.

• Reaffirmed Full-Year EPS Guidance

  Full-year 2026 adjusted diluted EPS guidance was maintained at $4.30-$4.45, indicating stronger underlying operating performance offsetting higher anticipated interest expenses from debt refinancing.

• Strategic Portfolio Shift

  The company is concentrating resources on higher-growth, higher-margin areas and has reduced gastroenterology product sales guidance due to the divestiture of the remaining portfolio.

auto_awesomeAnalysis

CONMED Corporation's first-quarter results demonstrate a positive shift following a challenging 2025, which saw a significant drop in net income and a dividend suspension. The company not only exceeded analyst expectations for both Q1 revenue and adjusted EPS but also raised its full-year organic revenue growth guidance. The reaffirmation of full-year adjusted EPS guidance, despite anticipating higher interest expenses from debt refinancing, signals stronger underlying operational performance. This indicates management's confidence in their strategic focus on higher-growth, higher-margin areas like minimally invasive surgery and orthopedic soft tissue repair, while divesting lower-margin gastroenterology products. Investors should view this as a strong indicator of operational improvement and potential stabilization after a period of headwinds.